EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

Qi Guo, Keval Parikh, Jian Zhang, Alexander Brinkley, Grace Chen, Natnicha Jakramonpreeya, Anjie Zhen, Dong Sung An

Molecular Therapy Methods & Clinical Development · 2025-06 · 33 (2) · 101486

DOI: 10.1016/j.omtm.2025.101486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-06. Verfasst von Qi Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic stem/progenitor cell (HSPC)-based anti-HIV-1 gene therapy holds promise to provide life-long remission following a single treatment. Here we report a multi-pronged anti-HIV-1 HSPC-based gene therapy designed to defend against and attack HIV-1 infection. We developed a lentiviral vector capable of co-expressing three anti-HIV-1 genes. Two are designed to prevent infection, including a short hairpin RNA (shRNA) (CCR5sh1005) to knock down HIV-1 co-receptor CCR5 and a membrane-anchored HIV-1 fusion inhibitor (C46). The third gene is a CD4-based chimeric antigen receptor (CAR) designed to attack HIV-1-infected cells. Our vector also includes a non-signaling truncated human epidermal growth factor receptor (huEGFRt) which acts as a negative selection-based safety kill switch against transduced cells. Anti-HIV-1 vector-transduced human CD34+ HSPC efficiently reconstituted multi-lineage human hematopoietic cells in humanized bone marrow/liver/thymus (huBLT) mice. HIV-1 viral load was significantly reduced (1-log fold reduction, p 4-fold reduction, p < 0.01) in huBLT mice. These results demonstrate that our strategy is highly effective for HIV-1 inhibition, and that CTX-mediated negative selection can deplete anti-HIV-1 vector-modified cells in the event of unwanted adverse effects in huBLT mice.

Schlagwörter

Stichwörter der Autor:innen

C46 membrane-anchored HIV-1 fusion inhibitorCCR5 short hairpin RNACD4-based anti-HIV-1 chimeric antigen receptorHIV-1cetuximab-mediated in vivo negative selection, humanized mousehematopoietic stem/progenitor cell (HSPC)-based gene therapytruncated human EGFR, huEGFRt

Autor:innen und Institutionen

  • UCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
  • UCLA School of Nursing, UCLA, Los Angeles, CA 90095, USA.
  • Shanghai Key Laboratory of Tumor System Regulation and Clinical Translation, Jiading Branch, Renji Hospital, Shanghai Cancer Institute, Shanghai 201800, China.
  • Department of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA.
  • Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand.
  • David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Guo, Q., Parikh, K., Zhang, J., Brinkley, A., Chen, G., Jakramonpreeya, N., Zhen, A., & An, D. S. (2025). Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Molecular Therapy Methods & Clinical Development, 33(2), 101486. https://doi.org/10.1016/j.omtm.2025.101486

Vancouver

Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, et al. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Molecular Therapy Methods & Clinical Development. 2025;33(2):101486. doi:10.1016/j.omtm.2025.101486

BibTeX
@article{Guo2025,
  author = {Guo, Qi and Parikh, Keval and Zhang, Jian and Brinkley, Alexander and Chen, Grace and Jakramonpreeya, Natnicha and Zhen, Anjie and An, Dong Sung},
  title = {Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection},
  journal = {Molecular Therapy Methods & Clinical Development},
  year = {2025},
  volume = {33},
  number = {2},
  pages = {101486},
  doi = {10.1016/j.omtm.2025.101486}
}
Kostenlos starten →